GSK 163090

Drug Profile

GSK 163090

Alternative Names: 163090; GSK-163090

Latest Information Update: 26 Jun 2012

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Serotonin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 26 Jun 2012 Discontinued before 2012 for Anxiety disorders in Germany (PO)
  • 26 Jun 2012 Discontinued before 2012 for Anxiety disorders in USA (PO)
  • 26 Jun 2012 Discontinued before 2012 for Major depressive disorder in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top